{"nctId":"NCT01244815","briefTitle":"Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","startDateStruct":{"date":"2011-06-16","type":"ACTUAL"},"conditions":["Bipolar Disorder, Pediatric"],"count":404,"armGroups":[{"label":"Asenapine 2.5 mg twice daily (BID)","type":"EXPERIMENTAL","interventionNames":["Drug: asenapine","Drug: Rescue medication"]},{"label":"Asenapine 5.0 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: asenapine","Drug: Rescue medication"]},{"label":"Asenapine 10.0 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: asenapine","Drug: Rescue medication"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to match asenapine","Drug: Rescue medication"]}],"interventions":[{"name":"asenapine","otherNames":["SCH 900274, Saphris"]},{"name":"Placebo to match asenapine","otherNames":[]},{"name":"Rescue medication","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participants who (or whose parent/legal representative) are able to give written informed consent.\n* Participants must be 10 years of age or older and 17 years of age or younger at the time of treatment assignment (randomization).\n* Participants must have a diagnosis of bipolar I disorder, confirmed by structured interview at screening.\n* Participants must not be pregnant or lactating, and those who are sexually active or become sexually active during the trial, and of child-bearing potential, must be using a medically accepted form of birth control.\n* Participants will be required to have stopped taking certain psycho-active medications prior to baseline.\n* Participants must have a caregiver, or other responsible person living with them who agrees to provide support to the participant to ensure study and procedure compliance.\n\nExclusion criteria:\n\n* Diagnosis of bipolar II disorder, or other form of bipolar or psychotic disorder.\n* Known or suspected mental retardation.\n* Substance abuse, or dependence, within the past 6 months.\n* There is risk of self-harm or harm to others.\n* There is a history of tardive dyskinesia or dystonia.\n* Pregnancy or lactation during the study.\n* History of seizure disorder.\n* Participation in any other clinical trial at the same time.\n* A family member who is part of the study staff or is directly involved with the study.\n* Other medical conditions determined by the study staff to possibly interfere with the study safety and efficacy evaluations.","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Y-MRS Total Score at Day 21","description":"The Y-MRS is an 11-item clinician-rated instrument for assessing the severity of manic episodes. A severity rating is assigned to each of the 11 items (Elevated mood, Increased motor activity-energy, Sexual interest, Sleep, Irritability, Speech, Language-thought disorder, Thought content, Disruptive-aggressive behavior, Appearance, Insight), based on the participant's subjective report of his or her condition over the previous 48 hours and the clinician's observations during the interview, with the emphasis on the latter. Seven of the 11 items are rated on a scale of 0-4 and 4 of the items are rated on a scale of 0-8, with higher scores indicating greater severity of symptoms. The Y-MRS total score for each participant is the sum of the ratings for the 11 individual items, and can range from 0-60, with higher scores indicating greater severity of symptoms. The reported measure is the change from baseline at Day 21; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"7.8"},{"groupId":"OG001","value":"-12.3","spread":"9.0"},{"groupId":"OG002","value":"-15.1","spread":"9.5"},{"groupId":"OG003","value":"-15.9","spread":"9.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression Scale for Use in Bipolar Disorder (CGI-BP) Overall Score at Day 21","description":"Change from baseline in CGI-BP overall score at Day 21 is the Key Secondary Outcome Measure. The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the participant's overall bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 21; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.9"},{"groupId":"OG001","value":"-1.3","spread":"1.1"},{"groupId":"OG002","value":"-1.4","spread":"1.0"},{"groupId":"OG003","value":"-1.4","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Total Y-MRS 50% Responders at Days 4, 7, 14 and 21","description":"A total Y-MRS 50% responder was defined as a participant who had a reduction from baseline to the identified study visit of at least 50% in the Y-MRS total score. The Y-MRS is an 11-item clinician-rated instrument for assessing the severity of manic episodes. A severity rating is assigned to each of the 11 items, based on the participant's subjective report of his or her condition over the previous 48 hours and the clinician's observations during the interview, with the emphasis on the latter. The Y-MRS total score for each participant is the sum of the ratings for the 11 individual items, and can range from 0-60 with higher scores indicating greater severity of symptoms. This analysis used a Last-Observation-Carried-Forward (LOCF) approach; if at a given visit no Y-MRS total score was available for determining whether a participant was a responder, the last available post-baseline on-treatment assessment prior to that visit was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Mania Score at Day 4","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the mania component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 4; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.6"},{"groupId":"OG001","value":"-0.6","spread":"0.8"},{"groupId":"OG002","value":"-0.5","spread":"0.7"},{"groupId":"OG003","value":"-0.5","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Mania Score at Day 7","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the mania component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 7; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.7"},{"groupId":"OG001","value":"-0.9","spread":"0.9"},{"groupId":"OG002","value":"-0.9","spread":"1.0"},{"groupId":"OG003","value":"-0.9","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Mania Score at Day 14","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the mania component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 14; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.0"},{"groupId":"OG001","value":"-1.1","spread":"1.0"},{"groupId":"OG002","value":"-1.4","spread":"1.0"},{"groupId":"OG003","value":"-1.3","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Mania Score at Day 21","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the mania component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 21; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.9"},{"groupId":"OG001","value":"-1.3","spread":"1.1"},{"groupId":"OG002","value":"-1.5","spread":"1.1"},{"groupId":"OG003","value":"-1.4","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Depression Score at Day 4","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the depression component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 4; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.7"},{"groupId":"OG001","value":"-0.3","spread":"0.8"},{"groupId":"OG002","value":"-0.2","spread":"1.0"},{"groupId":"OG003","value":"-0.1","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Depression Score at Day 7","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the depression component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 7; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.9"},{"groupId":"OG001","value":"-0.5","spread":"0.8"},{"groupId":"OG002","value":"-0.5","spread":"1.1"},{"groupId":"OG003","value":"-0.5","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Depression Score at Day 14","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the depression component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 14; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.1"},{"groupId":"OG001","value":"-0.5","spread":"1.0"},{"groupId":"OG002","value":"-0.7","spread":"1.0"},{"groupId":"OG003","value":"-0.6","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-BP Depression Score at Day 21","description":"The CGI-BP is a clinician-rated instrument for assessing bipolar illness that includes subscales assessing mania and depression. This measure reports one item within the CGI-BP, which is a 7-point scale assessing the severity of the depression component of the participant's bipolar illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from baseline at Day 21; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.0"},{"groupId":"OG001","value":"-0.6","spread":"1.1"},{"groupId":"OG002","value":"-0.8","spread":"1.1"},{"groupId":"OG003","value":"-0.6","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score at Day 7","description":"The CDRS-R is a 17-item clinician-rated instrument for assessing the presence and severity of depressive symptoms in children. Fourteen of the 17 items are rated on a scale of 1-7 and 3 of the items are rated on a scale of 1-5, with higher scores indicating greater severity of symptoms. The CDRS-R total score for each participant is the sum of the ratings for the 17 individual items, and can range from 17-113, with higher scores indicating greater severity of symptoms. The reported measure is the change from baseline at Day 7; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"8.1"},{"groupId":"OG001","value":"-6.1","spread":"7.1"},{"groupId":"OG002","value":"-6.1","spread":"8.0"},{"groupId":"OG003","value":"-5.9","spread":"8.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDRS-R Total Score at Day 14","description":"The CDRS-R is a 17-item clinician-rated instrument for assessing the presence and severity of depressive symptoms in children. Fourteen of the 17 items are rated on a scale of 1-7 and 3 of the items are rated on a scale of 1-5, with higher scores indicating greater severity of symptoms. The CDRS-R total score for each participant is the sum of the ratings for the 17 individual items, and can range from 17-113, with higher scores indicating greater severity of symptoms. The reported measure is the change from baseline at Day 14; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"8.1"},{"groupId":"OG001","value":"-5.8","spread":"6.5"},{"groupId":"OG002","value":"-8.7","spread":"10.5"},{"groupId":"OG003","value":"-6.6","spread":"8.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDRS-R Total Score at Day 21","description":"The CDRS-R is a 17-item clinician-rated instrument for assessing the presence and severity of depressive symptoms in children. Fourteen of the 17 items are rated on a scale of 1-7 and 3 of the items are rated on a scale of 1-5, with higher scores indicating greater severity of symptoms. The CDRS-R total score for each participant is the sum of the ratings for the 17 individual items, and can range from 17-113, with higher scores indicating greater severity of symptoms. The reported measure is the change from baseline at Day 21; improvement in symptoms is represented by negative values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"8.8"},{"groupId":"OG001","value":"-6.9","spread":"7.3"},{"groupId":"OG002","value":"-8.7","spread":"11.4"},{"groupId":"OG003","value":"-6.8","spread":"8.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Day 21","description":"CGAS is a 100-point scale measuring psychological, social, and school functioning in children aged 6-17. Minimum scores ranged from 1-10, representing the need for constant supervision (worse result) to maximum scores of 91-100, representing superior functioning (better result). The reported measure is the change from baseline at Day 21; improvement in functioning is represented by positive values. This analysis used an LOCF approach; if no Day 21 value was available for a participant, the last available post-baseline on-treatment assessment prior to the Day 21 assessment was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"8.1"},{"groupId":"OG001","value":"9.4","spread":"9.5"},{"groupId":"OG002","value":"13.0","spread":"11.6"},{"groupId":"OG003","value":"10.8","spread":"9.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score at Day 21","description":"PQ-LES-Q is a questionnaire to assess quality of life enjoyment and satisfaction in children and adolescents. The participant is asked to rate 15 items reflecting quality of life with respect to the previous week on a scale of 1=very poor to 5=very good. Items 1-14 assess specific areas (e.g., your health, your mood or feelings); Item 15 is a global assessment of overall quality of life. The PQ-LES-Q total score for each participant was calculated as the sum of the rating assigned to each of the first 14 items, and ranged from 14 to 70 with a higher score indicating better quality of life. The reported measure is the change from baseline at Day 21; improvement in quality of life is represented by positive values. This analysis used an LOCF approach; if no Day 21 value was available for a participant, the last available post-baseline on-treatment assessment prior to the Day 21 assessment was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"8.2"},{"groupId":"OG001","value":"3.7","spread":"8.6"},{"groupId":"OG002","value":"2.5","spread":"10.8"},{"groupId":"OG003","value":"4.0","spread":"9.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PQ-LES-Q Overall Score (i.e., Item 15) at Day 21","description":"PQ-LES-Q is a questionnaire to assess quality of life enjoyment and satisfaction in children and adolescents. The participant is asked to rate 15 items reflecting quality of life with respect to the previous week on a scale of 1=very poor to 5=very good. Items 1-14 assess specific areas (e.g., your health, your mood or feelings); Item 15 is a global assessment of overall quality of life. The Item 15 result is defined to be the PQ-LES-Q overall score, and ranged from 1 to 5 with a higher score indicating better quality of life. The reported measure is the change from baseline at Day 21; improvement in quality of life is represented by positive values. This analysis used an LOCF approach; if no Day 21 value was available for a participant, the last available post-baseline on-treatment assessment prior to the Day 21 assessment was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.9"},{"groupId":"OG001","value":"0.4","spread":"1.0"},{"groupId":"OG002","value":"0.1","spread":"1.0"},{"groupId":"OG003","value":"0.2","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":101},"commonTop":["SOMNOLENCE","HYPOAESTHESIA ORAL","SEDATION","HEADACHE","PARAESTHESIA ORAL"]}}}